Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical stage biopharmaceutical company that regularly issues news about its precision oncology pipeline and Generative Phosphoproteomics AP3 platform. Company announcements describe progress for its lead CHK1/CHK2 inhibitor ACR-368 in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, as well as updates on ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, and AP3-enabled preclinical programs such as the CDK11-targeting candidate ACR-6840.
News releases from Acrivon often cover interim clinical data, including response rates and tumor shrinkage in AP3-prioritized solid tumor types, details on dose-escalation cohorts, and observations of drug target engagement based on AP3 profiling. The company also reports on regulatory designations, such as FDA Fast Track status for ACR-368 monotherapy in endometrial cancer and FDA Breakthrough Device designation for the ACR-368 OncoSignature assay, as well as trial design elements like biomarker-selected and biomarker-unselected arms and combinations with ultra-low dose gemcitabine.
Investors and observers following ACRV news can expect updates on Acrivon’s presentations at scientific conferences, including AACR and AACR-NCI-EORTC, where the company highlights AP3-based mechanistic data, the AP3 KaiSR generative AI model, and pharmacodynamic insights for ACR-2316 and other candidates. The company also issues periodic financial results and business highlights, summarizing cash resources, research and development activities, and anticipated clinical and regulatory milestones for its AP3-enabled pipeline.
This ACRV news page aggregates these press releases and related coverage, providing a centralized view of Acrivon’s reported clinical progress, platform developments, and corporate updates over time.
Acrivon Therapeutics (Nasdaq: ACRV) reported clinical and financial results on March 19, 2026. Key clinical data show a confirmed overall response rate (cORR) of 52% in serous endometrial cancer versus 22% in non-serous subjects. The company initiated Arm 3 in late 2025 and plans Arm 4 in H1 2026. Cash, cash equivalents and marketable securities totaled $118.6 million as of December 31, 2025, expected to fund operations into Q2 2027. Net loss was $19.0M for Q4 2025 and $77.9M for full-year 2025.
Acrivon Therapeutics (Nasdaq: ACRV) will present preclinical and late-breaking AACR 2026 data showing ACR-368 synergizes with Topo 1 ADC payloads and with PD-L1 blockade, and ACR-2316 plus anti-PD-L1 produced complete, durable tumor regressions in mouse models.
The company noted its AP3 platform guided these combination discoveries; ACR-368 is in a registrational-intent Phase 2b and ACR-2316 is in Phase 1.
Acrivon Therapeutics (Nasdaq: ACRV) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 at 1:50 p.m. ET.
Peter Blume-Jensen, M.D., Ph.D., president and CEO, will appear in a fireside chat. A live and archived webcast will be available via the company's Events & Presentations investor webpage.
Acrivon (Nasdaq: ACRV) will host a live webcast KOL panel on February 27, 2026 at 8:00 a.m. ET to discuss maturing data from the registrational-intent Phase 2b ACR-368 endometrial cancer study and a late-breaking oral presentation at ESGO.
The event features international gynecologic oncology experts and an oral presentation of interim ACR-368 clinical data by Panos Konstantinopoulos, M.D., Ph.D. Webcast and archived video will be available via the company’s Events & Presentations investor page.
Acrivon Therapeutics (Nasdaq: ACRV) has completed and received CLIA certification for a wholly-owned clinical laboratory in Watertown, Massachusetts, expected to be fully operational in H1 2026. The facility will support patient testing and internal development of companion diagnostics.
The in-house CLIA lab aims to accelerate AP3-driven biomarker discovery, streamline co-regulatory workflows, and improve speed and cost-efficiency for precision medicine programs and potential partner collaborations.
Acrivon Therapeutics (Nasdaq: ACRV) announced a late-breaking oral presentation of interim clinical data for ACR-368 in endometrial cancer from its registrational-intent Phase 2b study (ACR-368-201/GOG3082, NCT05548296) at the ESGO 27th Annual Congress in Copenhagen, Feb 26-28, 2026.
Presenter Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., will present on Feb 27, 2026 at 12:05 p.m. CET (Presentation No. ESGO-2026-1321). The company described the interim data as a compelling clinical profile in a high unmet-need population.
Acrivon Therapeutics (Nasdaq: ACRV) reported interim clinical progress across its pipeline. Key Phase 2b ACR-368 EDC data show a 39% ORR overall and 44% ORR in subjects with ≤2 prior lines of therapy, with a confirmed ORR 67% in BM+ serous endometrial cancer (N=12) and 52% cORR in all serous subjects (N=23). Arm 3 (ACR-368 + ultra-low dose gemcitabine) will enroll up to 90 serous subjects without biopsy, targeting completion in Q4 2026 and EU sites to start in Q1 2026. Company submitted a Phase 3 protocol for ACR-368+anti-PD-1 and expects global readiness mid-2026. ACR-2316 Phase 1 (N=33) established dose regimens with tumor shrinkage in 9/20 evaluable patients and confirmed PR in endometrial cancer. ACR-6840 (CDK11) IND planned Q4 2026. Cash, cash equivalents and investments ~$119M as of 12/31/2025, funding into Q2 2027.
Acrivon Therapeutics (Nasdaq: ACRV) will release clinical updates via press release at 7:30 a.m. ET and host a conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026.
Planned disclosures include updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study, an update on a recently initiated tumor biopsy-independent Phase 2b arm, and details on the planned confirmatory Phase 3 trial. The company will also present initial Phase 1 data for ACR-2316 (WEE1/PKMYT1 inhibitor) covering safety, dosing regimen, and early clinical activity across AP3-prioritized solid tumors, plus nomination of a new preclinical development candidate in the AP3-driven cell cycle program.
A live webcast will be available from the company’s Events & Presentations page at https://ir.acrivon.com/news-events/events-presentations.
Acrivon Therapeutics (Nasdaq: ACRV) will provide clinical updates and pipeline news via a webcast and conference call in January 2026. Planned topics include updated interim ACR-368 data from the registrational-intent Phase 2b study, an update on the newly initiated tumor biopsy-independent Phase 2b arm, plans for a confirmatory Phase 3 trial, initial Phase 1 data for ACR-2316 (WEE1/PKMYT1 inhibitor) including safety, dosing and early activity, and nomination of a new preclinical AP3-driven cell cycle candidate with target disclosure.
Acrivon Therapeutics (Nasdaq: ACRV) said it will present clinical updates in January 2026 covering ACR-368 and ACR-2316 and other AP3 pipeline news.
Key topics include an updated interim ACR-368 readout from the registrational-intent Phase 2b study, an update on a recently initiated tumor biopsy-independent Phase 2b arm, and the company’s planned confirmatory Phase 3 trial. The company will also provide initial Phase 1 data for ACR-2316 (WEE1/PKMYT1 inhibitor) covering safety, dosing regimen, and early clinical activity across AP3-prioritized solid tumors, plus nomination of a new preclinical development candidate with target disclosure for its AP3-driven cell cycle program.